AI Portfolio Summary
In 2025 Q4, Eversept Partners, LP maintained a portfolio of 123 distinct positions. The most significant new addition to the portfolio was SPDR S&P 500 ETF TR, which now represents 1.54% of the total fund value. They heavily accumulated shares in VERA THERAPEUTICS IN, increasing their position by 9.4%. The fund also reduced its exposure to REVVITY INC by 58.7%.
Total Positions
123
Quarter
2025 Q4
Top Holding
VERA (7.8%)
Top 10 Concentration
47.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 123
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
VERA
VERA THERAPEUTI...
|
Healthcare | 7.84% | 5.62% |
#1
4
Prev: #5
|
7.1 | 264,468 | 9.4% |
P
S
|
3,072,304 | $155,581,475 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QQQ
PUT
INVESCO QQQ TR
|
PUT Option | 6.97% | 9.52% |
#2
1
Prev: #1
|
4.8 | -5,000 | -2.2% |
P
S
|
225,000 | $138,219,750 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GSK
GSK PLC
|
Healthcare | 6.62% | 6.31% |
#3
Prev: #3
|
6.1 | 559,275 | 26.4% |
P
S
|
2,679,721 | $131,413,518 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 6.20% | 7.32% |
#4
2
Prev: #2
|
3.5 | -628 | -0.2% |
P
S
|
252,592 | $123,075,452 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 4.47% | 2.50% |
#5
7
Prev: #12
|
5.3 | 231,335 | 54.2% |
P
S
|
657,834 | $88,712,204 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Healthcare | 3.86% | 5.76% |
#6
2
Prev: #4
|
1.5 | -185,151 | -35.6% |
P
S
|
334,493 | $76,629,001 | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 3.51% | 3.68% |
#7
1
Prev: #6
|
1.9 | -152,906 | -4.4% |
P
S
|
3,314,408 | $69,635,712 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 2.79% | 2.86% |
#8
2
Prev: #10
|
1.6 | -142,071 | -7.4% |
P
S
|
1,782,235 | $55,463,153 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 2.78% | 3.53% |
#9
2
Prev: #7
|
1.6 | -224,261 | -15.8% |
P
S
|
1,197,722 | $55,262,893 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 2.26% | 2.33% |
#10
5
Prev: #15
|
1.4 | -242,236 | -17.1% |
P
S
|
1,174,968 | $44,895,527 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HCA
HCA HEALTHCARE ...
|
Healthcare | 2.26% | 3.28% |
#11
2
Prev: #9
|
1.4 | -15,826 | -14.2% |
P
S
|
95,874 | $44,759,736 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
DANAHER CORPORA...
|
Healthcare | 2.15% | 1.36% |
#12
10
Prev: #22
|
3.9 | 86,989 | 87.6% |
P
S
|
186,262 | $42,639,097 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 2.15% | 2.43% |
#13
Prev: #13
|
1.4 | -443 | -0.1% |
P
S
|
538,218 | $42,578,426 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 1.96% | 2.06% |
#14
3
Prev: #17
|
3.3 | 280,805 | 24.3% |
P
S
|
1,434,725 | $38,967,131 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BRKR
BRUKER CORP
|
Healthcare | 1.86% | 1.54% |
#15
4
Prev: #19
|
2.7 | 96,660 | 14.1% |
P
S
|
783,789 | $36,924,300 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTR
AVANTOR INC
|
Healthcare | 1.83% | 0.80% |
#16
15
Prev: #31
|
3.7 | 2,252,202 | 243.6% |
P
S
|
3,176,644 | $36,404,340 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPY
PUT
SPDR S&P 500 ET...
|
PUT Option | 1.54% | — |
#17
Prev: #—
|
4.1 | 44,900 | no change |
NEW
|
44,900 | $30,618,208 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYH
COMMUNITY HEALT...
|
Healthcare | 1.25% | 1.54% |
#18
2
Prev: #20
|
2.5 | 993,751 | 14.3% |
P
S
|
7,943,802 | $24,784,662 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXAS
EXACT SCIENCES ...
|
Healthcare | 1.24% | — |
#19
Prev: #—
|
4.0 | 241,678 | no change |
NEW
|
241,678 | $24,544,818 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 1.18% | 0.72% |
#20
14
Prev: #34
|
3.5 | 1,619,270 | 117.9% |
P
S
|
2,992,895 | $23,344,581 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GERN
GERON CORP
|
Healthcare | 1.17% | 1.19% |
#21
2
Prev: #23
|
3.0 | 5,060,981 | 40.2% |
P
S
|
17,659,983 | $23,311,178 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TECH
BIO-TECHNE CORP
|
Healthcare | 1.12% | 2.27% |
#22
6
Prev: #16
|
0.4 | -214,135 | -36.2% |
P
S
|
377,405 | $22,195,188 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 1.10% | — |
#23
Prev: #—
|
3.9 | 98,721 | no change |
NEW
|
98,721 | $21,806,482 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PODD
INSULET CORP
|
Healthcare | 1.07% | 0.97% |
#24
1
Prev: #25
|
3.4 | 29,104 | 63.8% |
P
S
|
74,708 | $21,235,002 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBNX
BETA BIONICS IN...
|
Healthcare | 1.04% | — |
#25
Prev: #—
|
3.9 | 678,262 | no change |
NEW
|
678,262 | $20,666,643 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 1.04% | 1.90% |
#26
8
Prev: #18
|
0.4 | -703,476 | -51.6% |
P
S
|
660,177 | $20,604,124 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UNH
UNITEDHEALTH GR...
|
Healthcare | 1.01% | 1.49% |
#27
6
Prev: #21
|
0.9 | -1,958 | -3.1% |
P
S
|
60,862 | $20,091,155 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TLT
PUT
ISHARES TR
|
PUT Option | 1.01% | — |
#28
Prev: #—
|
3.9 | 230,000 | no change |
NEW
|
230,000 | $20,046,800 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
LIQUIDIA CORPOR...
|
Healthcare | 0.89% | 0.76% |
#29
3
Prev: #32
|
0.9 | 23,422 | 4.8% |
P
S
|
509,443 | $17,570,689 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ICLR
ICON PLC
|
Healthcare | 0.88% | 0.66% |
#30
6
Prev: #36
|
3.4 | 40,807 | 74.2% |
P
S
|
95,832 | $17,462,507 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HQY
HEALTHEQUITY IN...
|
Healthcare | 0.86% | 0.34% |
#31
18
Prev: #49
|
3.3 | 133,351 | 254.5% |
P
S
|
185,739 | $17,015,550 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GKOS
GLAUKOS CORP
|
Healthcare | 0.84% | — |
#32
Prev: #—
|
3.8 | 147,471 | no change |
NEW
|
147,471 | $16,650,951 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVTY
REVVITY INC
|
Healthcare | 0.79% | 2.38% |
#33
19
Prev: #14
|
0.3 | -231,534 | -58.7% |
P
S
|
162,777 | $15,748,675 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 0.74% | 0.96% |
#34
7
Prev: #27
|
0.8 | -67,765 | -13.9% |
P
S
|
420,827 | $14,762,611 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ESPR
ESPERION THERAP...
|
Healthcare | 0.72% | — |
#35
Prev: #—
|
3.8 | 3,851,133 | no change |
NEW
|
3,851,133 | $14,249,192 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIIB
BIOGEN INC
|
Healthcare | 0.69% | 0.50% |
#36
7
Prev: #43
|
3.3 | 26,179 | 50.6% |
P
S
|
77,944 | $13,717,365 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SEM
SELECT MED HLDG...
|
Healthcare | 0.68% | — |
#37
Prev: #—
|
3.8 | 906,100 | no change |
NEW
|
906,100 | $13,455,585 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNC
CENTENE CORP DE...
|
Healthcare | 0.67% | 0.55% |
#38
2
Prev: #40
|
2.8 | 99,542 | 44.3% |
P
S
|
324,092 | $13,336,386 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.65% | — |
#39
Prev: #—
|
3.8 | 308,466 | no change |
NEW
|
308,466 | $12,807,508 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 0.64% | — |
#40
Prev: #—
|
3.8 | 235,293 | no change |
NEW
|
235,293 | $12,691,704 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 0.64% | — |
#41
Prev: #—
|
3.8 | 5,391,548 | no change |
NEW
|
5,391,548 | $12,670,138 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 0.64% | 0.14% |
#42
27
Prev: #69
|
3.3 | 323,168 | 289.9% |
P
S
|
434,634 | $12,621,771 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.61% | — |
#43
Prev: #—
|
3.7 | 439,177 | no change |
NEW
|
439,177 | $12,187,162 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 0.61% | — |
#44
Prev: #—
|
3.7 | 99,400 | no change |
NEW
|
99,400 | $12,119,842 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 0.58% | — |
#45
Prev: #—
|
3.7 | 10,623 | no change |
NEW
|
10,623 | $11,416,326 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EHC
ENCOMPASS HEALT...
|
Healthcare | 0.57% | — |
#46
Prev: #—
|
3.7 | 106,926 | no change |
NEW
|
106,926 | $11,349,126 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 0.54% | — |
#47
Prev: #—
|
3.7 | 2,507,090 | no change |
NEW
|
2,507,090 | $10,680,203 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELV
ELEVANCE HEALTH...
|
Healthcare | 0.53% | 1.00% |
#48
24
Prev: #24
|
0.2 | -14,785 | -32.9% |
P
S
|
30,195 | $10,584,857 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNKD
MANNKIND CORP
|
Healthcare | 0.53% | 0.76% |
#49
16
Prev: #33
|
0.7 | -190,164 | -9.3% |
P
S
|
1,852,563 | $10,504,032 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.52% | — |
#50
Prev: #—
|
3.7 | 231,380 | no change |
NEW
|
231,380 | $10,370,452 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 123 holdings